Sanofi - ADR
SNY
Get informed when a big investor buys or sells
+ FollowEarnings Call Q4 2025
January 29, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
213.1% upsideUndervalued by 213.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $106.45 Billion |
|---|---|
| Enterprise Value | $121.87 Billion |
| Dividend Yield | $2.42 (5.38%) |
| Earnings per Share | $3.2 |
| Beta | 0.28 |
| Outstanding Shares | 2,408,400,000 |
Return
| Return on Equity | 14.22% |
|---|---|
| Return on Assets | 8.09% |
| Return on Invested Capital | 8.87% |
Valuation & Multiples
| P/E Ratio | 8.91 |
|---|---|
| PEG | -64.61 |
| Price to Sales | 1.84 |
| Price to Book Ratio | 1.48 |
| Enterprise Value to Revenue | 2.07 |
| Enterprise Value to EBIT | 14.02 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2499▼ 19.45% |
|---|---|
| Total Calls | 1,372,000▼ 14.87% |
| Total Puts | 1,714,820▼ 26.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.60%▼ 0.53% |
|---|---|
| Total Invested | $10.09B▼ 6.59% |
| Investors Holding | 751▼ 22.00% |
ESG Score
No data
About Sanofi
CEO: Paul Hudson Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the c...
Relevant Senate Committees
This powerful committee controls taxation (corporate tax rates, R&D credits), trade policy, and entitlement spending (Medicare and Medicaid drug coverage and pricing), all of which have a direct and significant impact on Sanofi's profitability and market access.
This committee allocates discretionary federal spending across all government functions. Its subcommittees directly determine the funding for health programs, scientific research, and public health initiatives that purchase pharmaceuticals and vaccines, directly impacting Sanofi's potential revenue.
This committee directly regulates the pharmaceutical industry through its oversight of the FDA (drug approval, manufacturing standards) and NIH (research funding), making it highly relevant to Sanofi's operations and product pipeline.
This committee's oversight of antitrust laws (impacting mergers and acquisitions) and intellectual property rights (patents, which are critical for pharmaceutical product exclusivity and R&D investment) directly affects Sanofi's core business model and valuation.